upcoming investor meetings
Category: 2023
Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy
nomination A Dubarry
Transgene reports business update and Q3 2023 financial position
Q3 2023 financial position
Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab)
Transgene and BioInvent – first patient treated in Part B of Phase I trial
Transgene advances its innovative immunotherapy pipeline and extends financial visibility until the end of 2024
2023 half year results and business update
Transgene Announces Upcoming Investor Meetings
Transgene Announces Upcoming Investor Meetings
Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers
C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication
Transgene receives $15.3 Million from the Sale of Securities Held for Sale
Transgene receives $15.3 million from the sale of securities held for sale
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
Transgene and NEC present New Data on TG4050 at ASCO 2023
Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023
Transgene immunological data demonstrating that TG4001 can induce T-cell responses
